Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
GYRE · Nasdaq · United States · Pharmaceutical Preparations
In shortGYRE THERAPEUTICS, INC. is profitable.
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 9.9% | 50/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.5% | 54/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 15.7% | 79/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 6.28× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.52 | 88/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -0.2% | 19/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -0.02× | 0/100 |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 585.2% | 0/100 |
| Operating margin volatility | 533.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 4.5% | 41/100 |
|---|---|---|
| EPS growth, 3-year average | -12.6% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 7.3 | 102 | 113 | 106 | 117 |
| Cost of revenue | – | 4.8 | 4.6 | 3.9 | 5.4 |
| Gross profit | – | 97 | 109 | 102 | 111 |
| Research & development | 69 | 17 | 14 | 12 | 14 |
| Operating income | (88) | 9.2 | (67) | 16 | 11 |
| Pre-tax income | (88) | 9.4 | (77) | 23 | 14 |
| Income tax | – | 5.1 | 8.5 | 5.3 | 4.6 |
| Net income | (88) | 4.3 | (85) | 18 | 9.9 |
| Diluted EPS | −$2.87 | $0.03 | −$1.41 | $0.05 | $0.02 |
| Diluted shares (millions) | 31 | 76 | 66 | 102 | 103 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of GYRE THERAPEUTICS, INC. are included in the Investor plan. Try free for 7 days →
4.52 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 7, 2026